Ardelyx, Inc. SEC filings ARDX

Ardelyx, Inc. has 1,006 filings in SEC EDGAR's recent list, going back to Jan 14, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
EFFECT Filing Jan 25, 2023 —
CORRESP Letter to the SEC Jan 24, 2023 —
UPLOAD Letter from the SEC Jan 23, 2023 —
DEFR14A Form defr14a May 13, 2022 —
EFFECT Filing Aug 3, 2020 —
CORRESP Letter to the SEC Jul 31, 2020 —
CORRESP Letter to the SEC Jul 23, 2020 —
UPLOAD Letter from the SEC Jul 14, 2020 —
CT ORDER Filing Apr 24, 2018 —
EFFECT Filing May 4, 2017 —
CORRESP Letter to the SEC May 3, 2017 —
UPLOAD Letter from the SEC May 2, 2017 —
EFFECT Filing Aug 24, 2016 —
CORRESP Letter to the SEC Aug 22, 2016 —
UPLOAD Letter from the SEC Aug 19, 2016 —
D Filing Aug 1, 2016 —

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ARDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Fremont, CA
SEC filer status
Large accelerated filer
SEC CIK
1437402
Former names
NTERYX INC (until Jun 9, 2008)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.